What are the alternatives to autologous stem cell transplant?

An autologous transplant collects your own blood-forming stem cells, gives intensive treatment, and returns those cells to help the marrow recover. If that approach is unsuitable, treatment may use chemotherapy or other systemic medicines without stem-cell rescue. An allogeneic transplant uses donor cells and can add a donor immune effect, but it also brings donor-related risks such as graft-versus-host disease.

CAR T-cell therapy modifies selected immune cells to recognise a cancer target. It is not suitable for every disease or person. Treatment choices vary across Hodgkin lymphoma, other lymphoma, and multiple myeloma, and depend on previous therapy, remission status, tumour biology, organ function, infection risk, and the person's priorities.

Ask the oncology team to set out the goal of each option, how quickly it needs to start, and what monitoring is required. Discuss fertility, hospital stays, infection precautions, hair loss, nerve symptoms, and effects on work or family responsibilities. Share all medicines and supplements, previous treatment records, and any history of heart, lung, kidney, or liver problems.

Report fever, chills, unusual bleeding, worsening breathlessness, severe vomiting, confusion, or sudden weakness promptly during cancer treatment. After immune or cellular therapy, urgent review is needed for a new rash, severe diarrhoea, speech or movement changes, or breathing difficulty. Keep scheduled blood tests and contact the treatment team before stopping a medicine.

Ask why an autologous transplant has been suggested and which alternatives match your cancer's current response. Ask whether a donor transplant or CAR T-cell therapy is feasible, what treatment would come first, and how the team would respond if the disease returned. Clarify who to call outside clinic hours.